D&O disclosure notice for Andy Eakin.
The pharmaceutical firm is pushing for approval of multiple phase-three trials in 2026.
Foot traffic is up, but margins are down.
Electricity generators are anxious to avoid winter power price spikes.
To join your company account for BusinessDesk and enjoy full access, enter your email and we’ll send you details